HYMPAVZI™ What is HYMPAVZI?
(marstacimab-hncq)
What is HYMPAVZI?
HYMPAVZI is a prescription medicine used to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.
It is not known if HYMPAVZI is safe and effective in children younger than 12 years old.
Before using HYMPAVZI, tell your healthcare provider about all of your medical conditions, including if you:
- •
- have a planned surgery. Your healthcare provider may stop treatment with HYMPAVZI before your surgery. Talk to your healthcare provider about when to stop using HYMPAVZI and when to start it again if you have a planned surgery.
- •
- have a severe short-term (acute) illness such as an infection or injury.
- •
- are pregnant or plan to become pregnant. HYMPAVZI may harm your unborn baby.
- Females who are able to become pregnant:
- o
- Your healthcare provider will do a pregnancy test before you start your treatment with HYMPAVZI.
- o
- You should use effective birth control (contraception) during treatment with HYMPAVZI and for 2 months after the last dose of HYMPAVZI.
- o
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with HYMPAVZI.
- •
- are breastfeeding or plan to breastfeed. It is not known if HYMPAVZI passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription medicines, over‑the‑counter medicines, vitamins, and herbal supplements.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Find HYMPAVZI™ medical information:
Find HYMPAVZI™ medical information:
HYMPAVZI™ Quick Finder
What is HYMPAVZI?
What is HYMPAVZI?
HYMPAVZI is a prescription medicine used to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.
It is not known if HYMPAVZI is safe and effective in children younger than 12 years old.
Before using HYMPAVZI, tell your healthcare provider about all of your medical conditions, including if you:
- •
- have a planned surgery. Your healthcare provider may stop treatment with HYMPAVZI before your surgery. Talk to your healthcare provider about when to stop using HYMPAVZI and when to start it again if you have a planned surgery.
- •
- have a severe short-term (acute) illness such as an infection or injury.
- •
- are pregnant or plan to become pregnant. HYMPAVZI may harm your unborn baby.
- Females who are able to become pregnant:
- o
- Your healthcare provider will do a pregnancy test before you start your treatment with HYMPAVZI.
- o
- You should use effective birth control (contraception) during treatment with HYMPAVZI and for 2 months after the last dose of HYMPAVZI.
- o
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with HYMPAVZI.
- •
- are breastfeeding or plan to breastfeed. It is not known if HYMPAVZI passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription medicines, over‑the‑counter medicines, vitamins, and herbal supplements.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
What is HYMPAVZI?
What is HYMPAVZI?
HYMPAVZI is a prescription medicine used to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.
It is not known if HYMPAVZI is safe and effective in children younger than 12 years old.
Before using HYMPAVZI, tell your healthcare provider about all of your medical conditions, including if you:
- •
- have a planned surgery. Your healthcare provider may stop treatment with HYMPAVZI before your surgery. Talk to your healthcare provider about when to stop using HYMPAVZI and when to start it again if you have a planned surgery.
- •
- have a severe short-term (acute) illness such as an infection or injury.
- •
- are pregnant or plan to become pregnant. HYMPAVZI may harm your unborn baby.
- Females who are able to become pregnant:
- o
- Your healthcare provider will do a pregnancy test before you start your treatment with HYMPAVZI.
- o
- You should use effective birth control (contraception) during treatment with HYMPAVZI and for 2 months after the last dose of HYMPAVZI.
- o
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with HYMPAVZI.
- •
- are breastfeeding or plan to breastfeed. It is not known if HYMPAVZI passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription medicines, over‑the‑counter medicines, vitamins, and herbal supplements.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Resources
Didn’t find what you were looking for? Contact us.
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Contact Medical Information.9AM-5PM ET Monday to Friday; excluding holidays.
Report Adverse Event
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.